Gilead dives deeper into Nurix protein degrader collab, paying $15M for 2-year extension

Gilead Sciences' collaboration with Nurix Therapeutics has already borne fruit in the form of one IRAK4 degrader. Now, the Big Biotech is handing over a further $15 million in the hope that prolonging the partnership will yield further bounty.